NCT00820768 is a Phase 1 clinical trial of ABI-010 in Solid Tumor, sponsored by Celgene.

Who is sponsoring NCT00820768?

NCT00820768 is sponsored by Celgene.

What drugs are being tested in NCT00820768?

Interventions in NCT00820768: ABI-010.

What condition does NCT00820768 study?

NCT00820768 studies Solid Tumor.

Is NCT00820768 still recruiting?

NCT00820768 is currently withdrawn. Last updated 11 April 2018.

Last reviewed 2018-04-11 · How we verify

NCT00820768

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Withdrawn Phase 1 Last updated 11 April 2018

What this trial tests

Phase 1 trial testing ABI-010 in Solid Tumor. Withdrawn.

Timeline

1 April 2012

Primary endpoint
1 April 2013

1 April 2014

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 April 2012
Primary completion	1 April 2013
Estimated completion	1 April 2014
Sites	1 location across United States

Drugs / interventions tested

ABI-010 — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine MTD and DLT of ABI-010 given weekly every three weeks followed by one week of rest (Cycle 1). Determine MLD and DLT in combination with ABI-007; to characterize the toxicities of ABI-010 alone and in combination with ABI-007.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation.
Cho H, Jeon SI, Ahn CH, Shim MK, et al · · 2022 · cited 80× · PMID 35456562 · DOI 10.3390/pharmaceutics14040728
Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review.
Van de Sande L, Cosyns S, Willaert W, Ceelen W. · · 2020 · cited 52× · PMID 31858848 · DOI 10.1080/10717544.2019.1704945
Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.
Vishnu P, Roy V. · · 2011 · cited 46× · PMID 21603258 · DOI 10.4137/bcbcr.s5857
Rationalized landscape on protein-based cancer nanomedicine: Recent progress and challenges.
Fan Z, Iqbal H, Ni J, Khan NU, et al · · 2024 · cited 11× · PMID 38511068 · DOI 10.1016/j.ijpx.2024.100238
The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity.
Xiong G, Jiang C, Schätzlein AG, Uchegbu IF. · · 2026 · PMID 41556287 · DOI 10.1080/10717544.2026.2614801

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00820768 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 11 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00820768.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing